Skip to main content

Table 3 Bleeding complications in patients with cancer treated with certoparin or UFH

From: Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

Pts with cancer at admission Certoparin UFH OR (95%CI) p-value*
  n/avail. % n/avail. %   
Patients with cancer at admission       
   with major bleeding 1/133 0.75 1/141 0.71 1.06 (0.07-17.13) 0.9669
   with minor bleeding 1/133 0.75 8/141 5.67 0.13 (0.02-1.02) 0.0523
  1. Legend: Pts, patients; SD, UFH, unfractionated heparin; OR, odds ratio; CI, confidence interval, * two-sided p-value for null-hypothesis: difference = 0 or odds ratio = 1.